TNK Therapeutics, Inc. logo

TNK Therapeutics, Inc.

TNK Therapeutics is a fully owned subsidiary of Sorrento Therapeutics, Inc. and utilizes Sorrentos G-MAB library to create novel chimeric antigen receptor (CAR) constructs for the generation of CAR.TNKs and other cellular therapies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Website
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
6042 Cornerstone Ct.West, Suite B, CA, 92121
San Diego
United States
Email
Contact Number

In Dec 2014, Sorrento entered into a global exclusive partnership with Conkwest, Inc., to codevelop CAR.TNK based cancer and infectious therapeutics. Presently, TNK Therapeutics is responsible for this colla.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

The CAR.TNK technology platform combines Conkwests Neukoplast cell line with Sorrentos proprietary G-MAB_ fully human antibody technology and CAR designs to further enhance the anti-cancer potency and tumor targeting of Neukoplast.

In Aug 2015, TNK Therapeutics, acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two undisclosed privately-held biotechnology companies.

In Nov 2016, TNK Therapeutics acquired Virttu Biologics, based at Glasgow, Scotland, developing oncolytic virus therapy for treatment of cancer. Virttus lead product candidate Seprehvirë (HSV1716) is a Herpes Simplex Virus (HSV)-based oncolytic virus that selectively kills cancer cells and eliciting an anti-tumor immune response in the patient.